Camurus Partners with Eli Lilly for Long-Acting Incretin Therapies

Camurus AB ( (SE:CAMX) ) has issued an announcement.

Camurus has entered a collaboration and license agreement with Eli Lilly, granting Lilly exclusive rights to develop and commercialize long-acting incretin products for cardiometabolic health using Camurus’ FluidCrystal technology. This partnership could bring Camurus up to $870 million in milestone payments and royalties, enhancing its market presence in the rapidly expanding field of metabolic diseases while allowing it to maintain its focus on CNS and rare diseases.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

More about Camurus AB

Camurus is an international, science-led biopharmaceutical company headquartered in Lund, Sweden, focused on developing and commercializing innovative, long-acting medicines for severe and chronic diseases. The company’s proprietary FluidCrystal technology is central to its R&D efforts, with a pipeline addressing dependence, pain, cancer, and endocrine diseases. Camurus operates across Europe, the US, and Australia, and is listed on Nasdaq Stockholm.

Average Trading Volume: 98,323

Current Market Cap: SEK30.35B

Learn more about CAMX stock on TipRanks’ Stock Analysis page.